Type 1 Diabetes - How the HHM System Evaluates Its Performance
|
|
- Heather Montgomery
- 3 years ago
- Views:
Transcription
1 511730DSTXXX / Journal of Diabetes Science and TechnologyFinan et al research-article2014 Original Article Closed-Loop Control Performance of the Hypoglycemia-Hyperglycemia Minimizer (HHM) System in a Feasibility Study Journal of Diabetes Science and Technology 2014, Vol. 8(1) Diabetes Technology Society Reprints and permissions: sagepub.com/journalspermissions.nav DOI: / dst.sagepub.com Daniel A. Finan, PhD 1, Thomas W. McCann Jr, MBA 1, Linda Mackowiak, MS 1, Eyal Dassau, PhD 2,3, Stephen D. Patek, PhD 4, Boris P. Kovatchev, PhD 4, Francis J. Doyle III, PhD 2,3, Howard Zisser, MD 2,3, Henry Anhalt, DO 1, and Ramakrishna Venugopalan, PhD 1 Abstract Background: This feasibility study investigated the insulin-delivery characteristics of the Hypoglycemia-Hyperglycemia Minimizer (HHM) System an automated insulin delivery device in participants with type 1 diabetes. Methods: Thirteen adults with type 1 diabetes were enrolled in this nonrandomized, uncontrolled, clinical-research-centerbased feasibility study. The HHM System comprised a continuous subcutaneous insulin infusion pump, a continuous glucose monitor (CGM), and a model predictive control algorithm with a safety module, run on a laptop platform. Closed-loop control lasted approximately 20 hours, including an overnight period and two meals. Results: When attempting to minimize glucose excursions outside of a prespecified target zone, the predictive HHM System decreased insulin infusion rates below the participants preset basal rates in advance of below-zone excursions (CGM < 90 mg/dl), and delivered 80.4% less insulin than basal during those excursions. Similarly, the HHM System increased infusion rates above basal during above-zone excursions (CGM > 140 mg/dl), delivering 39.9% more insulin than basal during those excursions. Based on YSI, participants spent a mean ± standard deviation (SD) of 0.2 ± 0.5% of the closed-loop control time at glucose levels < 70 mg/dl, including 0.3 ± 0.9% for the overnight period. The mean ± SD glucose based on YSI for all participants was ± 23.5 mg/dl. There were nine instances of algorithm-recommended supplemental carbohydrate administrations, and there was no severe hypoglycemia or diabetic ketoacidosis. Conclusions: Results of this study indicate that the current HHM System is a feasible foundation for development of a closed-loop insulin delivery device. Keywords algorithm, artificial pancreas, closed-loop control, model predictive control, type 1 diabetes Developing a closed-loop insulin delivery system has the potential to transform diabetes management and improve the lives of those living with the disease. Since JDRF (formerly the Juvenile Diabetes Research Foundation) launched the Artificial Pancreas Project in 2006, 1 various studies have reported the feasibility of different closed-loop algorithms to control blood glucose levels in patients with type 1 diabetes. 2-6 Although much technical progress has been made, patients with type 1 diabetes carry a significant burden in the completion of day-to-day diabetes care tasks, and run the continual risk of hypoglycemia and hyperglycemia in their attempts to achieve optimal glucose control. 7 Preliminary data from the Hypoglycemia-Hyperglycemia Minimizer (HHM) System, an automated insulin delivery device, are presented in this article. The control algorithm of the HHM System is designed to take action to reduce if not prevent glucose excursions outside of a prespecified target zone by adjusting insulin delivery based on predictions of near-future glucose trends. Following US Food and Drug Administration (FDA) guidance in preparation for human clinical trials, realistic aspects of the HHM System were investigated in silico, including protocol specifications and system characteristics. 8 The virtual cohort investigated comprised 100 adult patients, and has been accepted by the FDA as suitable replacement for animal studies. 9 1 Animas Corporation, West Chester, PA, USA 2 University of California, Santa Barbara, Santa Barbara, CA, USA 3 Sansum Diabetes Research Institute, Santa Barbara, CA, USA 4 University of Virginia, Charlottesville, VA, USA Corresponding Author: Daniel A. Finan, Animas Corporation, 965 Chesterbrook Blvd, Wayne, PA 19087, USA. dfinan@its.jnj.com
2 36 Journal of Diabetes Science and Technology 8(1) The design of the simulation study approximated the clinical study design as closely as possible, from both system and protocol perspectives. 10 From a system perspective, the algorithm used in the simulation study was identical to that planned for the clinical study. From a protocol perspective, two key parameters were intended to be adjustable throughout the clinical study to glean more targeted information: the ratios of prandial insulin boluses to the breakfast and lunch carbohydrate (CHO) quantities, relative to the nominal matched amounts based on the subject s insulinto-cho ratios. The stated values of mismatch planned for the study were: (a) for breakfast, a matched bolus or 30% underbolus; and (b) for lunch, a matched bolus or 30% overbolus. The rationale for this bolus mismatch stipulation was to ensure adequate glucose fluctuations and thereby investigate the algorithm s insulin-dosing characteristics in response to potential hypoglycemic and hyperglycemic excursions. All stated values for these boluses were investigated in silico to demonstrate safety in the clinical study. The results from the simulations did not indicate any safety concerns, regardless of the bolus mismatch parameters, and provided sufficient justification for moving forward with the clinical (feasibility) study. 11,12 The feasibility study was executed to evaluate the performance of the HHM System in participants with type 1 diabetes in a clinical research center (CRC) setting. The primary objective of this study was to investigate the insulin delivery characteristics of the HHM System before and during glucose excursions below and above a prespecified target zone of mg/dl. As the study was unpowered, targeted metrics were designed and used to assess the potential of the HHM System to safely maintain glucose levels by adjusting insulin infusion amounts in quiescent times (including overnight) as well as in response to meal challenges. Methods Clinical Study Design This was a nonrandomized, uncontrolled, CRC-based feasibility study. The study was conducted in accordance with the Declaration of Helsinki, International Conference on Harmonisation, Good Clinical Practice guidelines, and relevant local laws and regulations. The protocol and informed consent form were approved by Compass Independent Review Board, LLC (Mesa, AZ), and all participants provided written informed consent. The study objectives were to evaluate the performance of the HHM System in participants with type 1 diabetes in a CRC setting; investigate the insulin delivery characteristics of the HHM System in anticipation of, and during, glucose excursions below and above a prespecified target zone ( mg/dl); and assess the ability of the system to safely maintain glucose levels by adjusting insulin infusion amounts in response to challenges of food and insulin boluses. Table 1. Main Inclusion and Exclusion Criteria for Participation. Inclusion criteria Age years Diagnosed with type 1 diabetes for 1 year Using an insulin infusion pump for 6 months with commercially available rapid-acting insulin Hemoglobin A1c < 10% Exclusion criteria Pregnant/nursing Skin conditions that would preclude wearing study devices Diabetic ketoacidosis requiring an emergency room visit or hospitalization in the previous 6 months Severe hypoglycemia resulting in seizure or loss of consciousness in the previous 6 months History of a seizure disorder Use of oral prednisone or a beta-blocker Intolerant of or unable to receive glucagon Hematocrit level < 30% or > 55% Abnormal renal function (creatinine > 1.5 mg/dl) Subjects. The target cohort of this feasibility study was adults with type 1 diabetes using insulin pumps. Main inclusion and exclusion criteria are listed in Table 1. In addition, subjects with any other condition that, in the opinion of the investigator, would preclude successful participation in the clinical trial were excluded. Investigational device. In this study the investigational device, the HHM System, comprised a continuous glucose monitor (CGM), insulin pump, automatic control algorithm, and central laptop (Figure 1). 13 The algorithm of the HHM System had two modular components the Zone Model Predictive Controller (Zone- MPC) and the Safety Supervision Module (SSM) which worked to automatically and continuously dose insulin in response to changing CGM levels. The Zone-MPC algorithm used a mathematical approximation of insulin-glucose dynamics to predict near-future glucose trends from recent CGM measurements and insulin dosage amounts. CGM values are automatically input to the algorithm every 5 minutes. The algorithm was designed to deliver insulin as needed to maintain glucose levels within the target zone ( mg/ dl). 14 The SSM used mathematical approximations of the insulin-glucose dynamics to continually assess and mitigate the risk of near-future hypoglycemia. 15 It acted on the Zone- MPC s recommended insulin infusion amount, and was designed to provide an additional safeguard against predicted near-future hypoglycemia. The action of the SSM was constrained to approving or reducing (but not increasing) the insulin amount recommended by the Zone-MPC. Procedure. During the week before the CRC visit, individual participants basal rates were assessed and optimized by
3 Finan et al 37 The breakfast meal on day 2 was administered at approximately 07:00, and included 1 g CHO per kg body weight, up to a maximum of 100 g CHO. Coincident with the breakfast meal, an insulin bolus was administered, which in some cases was an underbolus by 30% relative to their insulin-to- CHO ratio. The purpose for this deliberate underinsulinization was to ensure adequate algorithm activity in mitigating the subsequent (potential) hyperglycemia. The lunch meal on day 2 was administered at approximately 13:00, and also included 1 g CHO per kg body weight, up to a maximum of 100 g CHO. Coincident with the lunch meal, an insulin bolus was administered, which in some cases was an overbolus by 30%. Similar to the rationale for the underbolus at the breakfast meal, the purpose for the deliberate overinsulinization at lunchtime was to ensure adequate algorithm activity in mitigating the subsequent (potential) hypoglycemia. The participant was discharged in the evening of day 2. Figure 1. The investigational device comprised a continuous subcutaneous insulin infusion pump (OneTouch Ping Glucose Management System; Animas Corporation, West Chester, PA), a continuous glucose monitoring system (Dexcom SEVEN PLUS Continuous Glucose Monitor; Dexcom, Inc, San Diego, CA), and the Hypoglycemia-Hyperglycemia Minimizer algorithm run on the University of California, Santa Barbara/Sansum Diabetes Research Institute Artificial Pancreas System (APS ) laptop platform. 11 RF, radiofrequency. the investigative staff. The individual basal rates were used by the algorithm of the HHM System as the default insulin delivery rates when CGM values were predicted to be within the target zone; by extension, when CGM values were (or were predicted to be) outside the target zone, these basal rates served as the basis insulin delivery rate from which the algorithm might increase or decrease insulin delivery. CGM sensor insertion occurred 2-3 days prior to the CRC visit and was calibrated by meter throughout the study per the manufacturer s instructions. The CRC visit lasted approximately 24 hours for each participant, including approximately 20 hours of closedloop control during which the HHM System was assessed. The sequence of events during the CRC visit was as follows: The participant arrived during the early evening of day 1. Closed-loop control was initiated at approximately 00:00 (midnight), and lasted until approximately 20:00. Glucose monitoring was performed using YSI 2300 STAT Plus (YSI Inc, Yellow Springs, OH) at the following time points: before meals and every 2 hours prior to enabling closed-loop control mode; every 30 minutes during closedloop control mode; every 20 minutes for 80 minutes following meals; every 15 minutes if hypoglycemic, until glucose rose > 80 mg/dl; and every 30 minutes if hyperglycemic until glucose fell < 300 mg/dl. All diabetes care in the CRC was performed by study staff. A follow-up telephone call was conducted 24 hours after the CRC visit. Data Analysis The ability of the HHM System to anticipate and to preemptively respond to predicted below-zone and above-zone excursions based on CGM values was assessed, as was its ability to respond during below-zone and above-zone excursions. These metrics quantified differences in the HHM System delivered insulin rates compared to the corresponding basal rates in the 15 minutes prior to an out-of-zone breach (defined as when the CGM tracing exited the glucose target zone), as well as any time during an out-of-zone excursion. Glucose control metrics were calculated, but should be considered with the caveat that the primary objective of the study was not to obtain optimal glucose control, but rather to investigate the insulin-delivery characteristics of the HHM System including during periods of over- and underinsulinization. Glucose metrics based on YSI and CGM were calculated for four time ranges: overall, overnight (approximately 00:00-07:00), post-breakfast (approximately 07:00-13:00),
4 38 Journal of Diabetes Science and Technology 8(1) Table 2. Patient Characteristics (N = 13). Parameter Value Age, years, mean ± SD 42.5 ± 12.7 Female, n (%) 11 (84.6) Body mass index, kg/m 2, mean ± SD 24.7 ± 5.1 Duration of diabetes, years, mean ± SD 27.2 ± 13.3 Duration of pump use, years, mean ± SD 9.6 ± 3.8 Hemoglobin A1c, %, mean ± SD 7.4 ± 0.8 Type of insulin used, % Humalog 53.8 Novolog 38.5 Apidra 7.7 SD, standard deviation. and post-lunch (approximately 13:00-20:00). Glucose metrics were assessed as the percentage of time spent in an approximately normoglycemic range ( mg/dl), a hyperglycemic range (> 180 mg/dl), and a hypoglycemic range (< 70 mg/dl) while in closed-loop control. Other calculated metrics included the mean glucose for all participants. Results Participant Characteristics The characteristics of the 13 participants who completed the study are summarized in Table 2. Insulin Infusion Characteristics of the HHM System The HHM System took significant preemptive, mitigating action prior to below-zone excursions (defined as the 15 minutes prior to a below-zone CGM breach) by delivering, on average, 77.2% less insulin than basal during these times (Table 3). The HHM System did not significantly increase dosing relative to basal in the times prior to above-zone excursions. During below-zone excursions, an average decrease of 80.4% in HHM System insulin infusion rates was observed compared with basal rates. During above-zone excursions an average increase of 39.9% in HHM System insulin infusion rates was observed compared with basal rates. 11 The algorithm response did not result in a significant increase or decrease in overall total daily dose relative to the participants basal/bolus therapy regimens, but rather in a redistribution of insulin delivery based on CGM data. There was a 10.6% increase in the average HHM System insulin infusion rate compared with the average basal rate. During the overnight period, the post-breakfast period, and the postlunch period the average HHM System infusion rate was 6.6%, 18.8%, and 3.8% greater than the average basal rate, respectively. The HHM System s insulin infusion rates stayed at approximately basal-level rates for 9.7% of the total time spent in closed-loop control, were higher than basal rates 47.4% of the time, and were lower 42.9% of the time. Overall, the average HHM System insulin infusion rate was 27% lower than that recommended by the Zone-MPC, reflecting the ability of the SSM to attenuate the insulin dose recommendations to mitigate the risk of hypoglycemia. The reductions in infusion rates by the SSM were 33.1% in the overnight period, 22.6% in the post-breakfast period, and 20.6% in the post-lunch period. Glucose Metrics Glucose metrics were calculated including the periods of deliberate underinsulinization and overinsulinization. Based on YSI measurements, participants spent on average 0.2 ± 0.5% of the closed-loop control time at glucose levels < 70 mg/dl and 69.6 ± 24.7% of the closed-loop control time at glucose levels mg/dl (Table 4). During the overnight period, participants spent 0.3 ± 0.9% of the time < 70 mg/dl and 81.8 ± 35.6% of the time between 70 and 180 mg/dl. During the post-breakfast and post-lunch periods, participants spent 0.3 ± 1.1% and 0% of the time < 70 mg/dl, respectively. 11 Based on CGM measurements, participants spent on average 0.5 ± 1.2% of the closed-loop control time at glucose levels < 70 mg/dl and 62.2 ± 20.2% of the closedloop control time at glucose levels mg/dl (Table 5). During the overnight period, participants spent 0.1 ± 0.3% of the time < 70 mg/dl and 80.0 ± 27.5% of the time between 70 and 180 mg/dl. During the post-breakfast and post-lunch periods, participants spent 1.5 ± 3.8% and 0% of the time < 70 mg/dl, respectively. 11 The mean ± SD glucose value based on YSI was ± 23.5 mg/dl; the mean ± SD based on CGM was ± 27.3 mg/dl. 12 For CGM excursions < 70 mg/dl (n = 3), the average area between the CGM curve and the threshold of 70 mg/dl was 0.35 mg/dl day overall and 1.69 mg/dl day for the postbreakfast period. 12 For excursions > 180 mg/dl, the average area between the CGM curve and the threshold of 180 mg/dl was 19.5 mg/dl day overall, 12.5 mg/dl day for the overnight period, 30.0 mg/dl day for the post-breakfast period, and 25.1 mg/dl day for the post-lunch period. Following initiation of closed-loop control, and leading up to the breakfast meal, there was an evident narrowing of the ± 1 SD band in the CGM tracings (Figure 2), indicating the HHM System s ability to control glucose to near-normoglycemic values during the overnight period. Based on YSI, the mean ± SD meal peaks for the breakfast and lunch meals were 241 ± 47 mg/dl and 200 ± 50 mg/dl, respectively, and based on CGM they were 265 ± 63 mg/dl and 224 ± 51 mg/ dl, respectively. Safety Events Under closed-loop control, there were a total of nine instances when the investigator administered algorithm-recommended CHO, which was 15 g of juice or glucose tablets (Table 6). Four of these instances occurred in one participant (participant 12). There were no instances of investigator-initiated
5 Finan et al 39 Table 3. Ability of the Hypoglycemia-Hyperglycemia Minimizer (HHM) System Algorithm to Modulate Insulin Delivery, Relative to the Participants Corresponding Basal Rates, Both Prior to and During Out-of-Zone Glucose Excursions. Below-zone excursions (n = 10) Above-zone excursions a (n = 27) Basal rate (mean ± SD; U/h) HHM rate (mean ± SD; U/h) % change from basal (mean) Basal rate (mean ± SD; U/h) HHM rate (mean ± SD; U/h) % change from basal (mean) Before excursions 0.77 ± ± ± ± During excursions 0.84 ± ± ± ± SD, standard deviation. a These metrics exclude the 60-minute period after meals due to the confounding effects of the meals and corresponding insulin boluses. Table 4. YSI Metrics While Under Closed-Loop Control: Percentage of Time Spent in Glucose Ranges of < 70 mg/dl, mg/dl, and > 180 mg/dl. % of time spent Overall Overnight, 00:00-07:00 Postbreakfast, 07:00-13:00 Postlunch, 13:00-20:00 Participant < >180 < >180 < >180 < >180 1 a a a a NA NA NA a Average Standard deviation NA, not applicable. a Indicates subjects who were deliberately under- and overbolused by 30% for breakfast and lunch, respectively. CHO administration (i.e., when the algorithm was not recommending CHO administration). There was one instance of investigator-initiated treatment for hyperglycemia, per protocol requirement (glucose level >300 mg/dl for 1 hour by YSI). At the time of this insulin dose, CGM glucose was decreasing, ketones were 0.1 mmol/l, and the participant was asymptomatic. Protocol-defined glucose-related safety events (severe hypoglycemia or diabetic ketoacidosis) did not occur in any study participants. There was one adverse device effect related to bruising and bleeding at sensor insertion site (an expected event), which occurred prior to the CRC visit. Continuous-Glucose-Monitoring-Related Issues There were 128 total instances of missed CGM samples (on average, 9.8 samples per participant). These missed CGM samples were due to radiofrequency communication issues or other communication issues related to the investigational setup, or due to display of??? on the CGM receiver, indicating that the sensor is sending glucose readings but the receiver does not understand. The longest consecutive string of 10 missed CGM samples was due to device communication malfunction. For many participants, the longest string of missed samples was only 1 or 2 samples (corresponding to 5 or 10 minutes real time), indicating that the algorithm is able to cope with some missing data and carry on safely. Discussion This feasibility study evaluated the performance of the HHM System in participants with type 1 diabetes in a CRC setting. This study demonstrated that the HHM System was able to
6 40 Journal of Diabetes Science and Technology 8(1) Table 5. Continuous Glucose Monitor Metrics While Under Closed-Loop Control: Percentage of Time Spent in Glucose Ranges of < 70 mg/dl, mg/dl, and > 180 mg/dl. % of time spent Overall Overnight, 00:00-07:00 Postbreakfast, 07:00-13:00 Postlunch, 13:00-20:00 Participant < >180 < >180 < >180 < >180 1 a a a a NA NA NA a Average Standard deviation NA, not applicable. a Indicates subjects who were deliberately under- and overbolused by 30% for breakfast and lunch, respectively. Table 6. Administrations of Algorithm-Recommended Supplemental Carbohydrates. Instance (sequentially) Participant YSI value at administration (mg/dl) CGM value at administration (mg/dl) Mean ± SD 86.2 ± ± 21.8 Figure 2. Average Hypoglycemia-Hyperglycemia Minimizer (HHM) System results for all participants (n = 13). Upper plot: Glucose levels (mean ± standard deviation) based on continuous glucose monitoring (CGM). Also shown are the nominal meal times. The shaded area is the approximately normoglycemic range ( mg/dl). Lower plot: HHM System determined insulin delivered during closed-loop control, as a percentage difference from the participants respective basal rates (mean ± standard deviation). modulate insulin delivery based on CGM readings, and was effective in taking preemptive action to mitigate near-future Each administration was 15 g of juice or glucose tablets. CGM, continuous glucose monitor; SD, standard deviation. below-zone excursions by delivering less insulin than the corresponding preprogrammed basal rates. The algorithm appeared to redistribute insulin delivery based on CGM data, without significantly altering the overall total daily basal dose. To mitigate out-of-zone excursions, the HHM System decreased insulin infusion rates by an average of 80.4% during below-zone excursions and increased infusion rates by an average of 39.9% during above-zone excursions.
7 Finan et al 41 The efficacy of the HHM System is further supported by the glucose data, which demonstrate that the system was able to maintain participants glucose in the approximately normoglycemic range ( mg/dl) most of the time (an average of 69.6% overall and 81.8% overnight, as measured by YSI) with very little time spent in the hypoglycemic range (< 1% of time with glucose levels < 70 mg/dl, as measured by both YSI and CGM). The safety data also support the feasibility of the HHM System. During the study, there were no instances of severe hypoglycemia or diabetic ketoacidosis, no instances of investigator-initiated CHO administration, and only one instance of investigator-initiated treatment for hyperglycemia. The nine instances of investigator-administered algorithmrecommended CHO served as a preliminary evaluation of the algorithm s warning capabilities, which will unquestionably be an important part of the overall HHM System. Although there were 128 instances of missed CGM samples (due to device communication or display issues, including related to investigational set-up), the algorithm was able to cope with the missing data and carry on safely. Recent studies have also demonstrated feasibility of overnight closed-loop control systems in clinical settings. 2,3,16,17 As in the current study, these studies demonstrate the feasibility of maintaining a majority of patients in (near) normoglycemia while mitigating the risk of hypoglycemia during defined periods of closed-loop control. Limitations of this research are inherent in a feasibility study and include the small sample size, the relatively short term of observation, and the artificial, sedentary CRC-based environment. As the study design included adjustment of food and insulin variables, the glucose outcomes need to be interpreted with caution. Conclusions The results of this study indicate that the HHM System is a feasible foundation for development of a closed-loop control insulin delivery device; further studies are under way. Abbreviations CGM, continuous glucose monitor; CHO, carbohydrate; CRC, clinical research center; FDA, Food and Drug Administration; HHM, Hypoglycemia-Hyperglycemia Minimizer; SD, standard deviation; SSM, Safety Supervision Module; Zone-MPC, Zone Model Predictive Controller. Authors Note ClinicalTrials.gov identifier: NCT Acknowledgments The authors would like to thank JDRF and the staff of Sansum Diabetes Research Institute for their participation in this study. The authors received editorial support from Excerpta Medica for preparation of this article. Parts of the study were presented as poster presentations at the 72nd Scientific Sessions of the American Diabetes Association (ADA), Philadelphia, PA (June 8-12, 2012) and at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD), Berlin, Germany (October 1-5, 2012). Declaration of Conflicting Interests The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Daniel A. Finan, Thomas W. McCann Jr, and Ramakrishna Venugopalan are employees of Animas Corporation. Linda Mackowiak and Henry Anhalt were employees of Animas Corporation at the time of execution of the study. Henry Anhalt is currently employed by Sanofi. Linda Mackowiak is a limited stockholder of Medtronic, Abbott, and Edwards Lifesciences. Eyal Dassau has received product support from Insulet Corporation. Stephen D. Patek and Francis J. Doyle III have no conflict of interest. Boris P. Kovatchev has acted on the advisory board/consulted for Animas Corporation and Sanofi-Aventis; and has received research grant and product support from Animas Corporation, Insulet Corporation, Roche Diagnostics, Sanofi-Aventis, and Tandem Diabetes Care. Howard Zisser has received honoraria for scientific lectures and travel reimbursement from Animas Corporation, Cellnovo, Insulet Corporation, MannKind Corporation, and Roche; and research grant and product support from Animas Corporation, Abbott Laboratories, Dexcom Inc, Eli Lilly and Co, GluMetrics Inc, Insulet Corporation, LifeScan Inc, Medtronic Inc, Novo Nordisk, Roche, and Sanofi; and is a board member of Artificial Pancreas Technologies. Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by JDRF and Animas Corporation. References 1. Kowalski AJ. Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technol Ther. 2009;11(suppl 1):S113-S Breton M, Farret A, Bruttomesso D, et al. Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes. 2012;61(9): Dassau E, Zisser H, Harvey RA, et al. Clinical evaluation of a personalized artificial pancreas. Diabetes Care. 2013;36(4): Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet. 2010;375(9716): Russell SJ, El-Khatib FH, Nathan DM, Magyar KL, Jiang J, Damiano ER. Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care. 2012;35(11): Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes. 2006;55(12):
8 42 Journal of Diabetes Science and Technology 8(1) 7. Cobelli C, Renard E, Kovatchev B. Artificial pancreas: past, present, future. Diabetes. 2011;60(11): U.S. Department of Health of Human Services. Guidance for industry and Food and Drug Administration staff. The content of investigational device exemption (IDE) and premarket approval (PMA) applications for artificial pancreas device systems. November 9, Available at: downloads/medicaldevices/deviceregulationandguidance/ GuidanceDocuments/UCM pdf. Accessed May 22, Kovatchev BP, Breton M, Man CD, Cobelli C. In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol. 2009;3(1): Patek SD, Bequette BW, Breton M, et al. In silico preclinical trials: methodology and engineering guide to closed-loop control in type 1 diabetes mellitus. J Diabetes Sci Technol. 2009;3(2): Venugopalan R, Finan DA, McCann Jr TW, et al. Performance metrics of the Hypoglycemia-Hyperglycemia Minimizer (HHM) System in a closed-loop feasibility study. Diabetes. 2012;61(suppl 1):A Mackowiak L, Finan DA, McCann Jr TW, Venugopalan R, Zisser H, Anhalt H. Feasibility study assessing Hypoglycemia- Hyperglycemia Minimizer (HHM) System in patients with type 1 diabetes (T1DM) in a clinical research center (CRC). Diabetes. 2012;61(suppl 1):A Dassau E, Zisser H, Palerm CC, Buckingham BA, Jovanovic L, Doyle FJ 3rd. Modular artificial beta-cell system: a prototype for clinical research. J Diabetes Sci Technol. 2008;2(5): Grosman B, Dassau E, Zisser HC, Jovanovic L, Doyle FJ 3rd. Zone model predictive control: a strategy to minimize hyper- and hypoglycemic events. J Diabetes Sci Technol. 2010;4(4): Hughes CS, Patek SD, Breton MD, Kovatchev BP. Hypoglycemia prevention via pump attenuation and red-yellow-green traffic lights using continuous glucose monitoring and insulin pump data. J Diabetes Sci Technol. 2010;4(5): Nimri R, Atlas E, Ajzensztejn M, Miller S, Oron T, Phillip M. Feasibility study of automated overnight closed-loop glucose control under MD-logic artificial pancreas in patients with type 1 diabetes: the DREAM Project. Diabetes Technol Ther. 2012;14(8): Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med. 2013;368(9):
Diabetes Care 36:801 809, 2013
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Clinical Evaluation of a Personalized Artificial Pancreas EYAL DASSAU, PHD 1,2,3 HOWARD ZISSER, MD 1,3 REBECCA A. HARVEY,
More informationStarting patients on the V-Go Disposable Insulin Delivery Device
Starting patients on the V-Go Disposable Insulin Delivery Device A simple guide for your practice For adult patients with Type 2 diabetes on basal insulin who need to take the next step Identify appropriate
More information[Frida Svendsen and Jennifer Southern] University of Oxford. October 2014
In adolescents with poorly controlled type 1 diabetes mellitus, could a bionic, bihormonal pancreas provide better blood glucose control than continuous subcutaneous insulin infusion therapy? [Frida Svendsen
More informationJDRF Type One Nation Research Summit Diabetes Technology: A Bridge to a Cure
JDRF Type One Nation Research Summit Diabetes Technology: A Bridge to a Cure Kelly L. Close, president, Close Concerns editor-in-chief, diatribe March 1, 2014 closeconcerns.com diatribe.org @diatribenews
More informationIntensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationAbstract SYMPOSIUM. Journal of Diabetes Science and Technology
Journal of Diabetes Science and Technology Volume 3, Issue 5, September 2009 Diabetes Technology Society SYMPOSIUM Closed-Loop Artificial Pancreas Using Subcutaneous Glucose Sensing and Insulin Delivery
More informationAlternative method for delivering insulin using continuous subcutaneous insulin infusion (CSII) open loop system
ISHP Spring CE Conference April 12, 2015 St. Luke s Medical Center Randi Lynn Griffiths, PharmD Clinical outpatient pharmacist Boise VA Medical Center Boise, Idaho Alternative method for delivering insulin
More informationOutpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes
original article Outpatient Glycemic with a Bionic Pancreas in Type 1 Diabetes Steven J. Russell, M.D., Ph.D., Firas H. El-Khatib, Ph.D., Manasi Sinha, M.D., M.P.H., Kendra L. Magyar, M.S.N., N.P., Katherine
More informationTitle: Using Formal Methods to Improve Safety of Home-Use Medical Devices
Title: Using Formal Methods to Improve Safety of Home-Use Medical Devices Authors: Ayan Banerjee Impact Lab, Arizona State University abanerj3@asu.edu Yi Zhang Center for Devices and Radiological Health,
More informationInsulin Initiation and Intensification
Insulin Initiation and Intensification ANDREW S. RHINEHART, MD, FACP, CDE MEDICAL DIRECTOR AND DIABETOLOGIST JOHNSTON MEMORIAL DIABETES CARE CENTER Objectives Understand the pharmacodynamics and pharmacokinetics
More informationNovel Insulin Delivery Profiles for Mixed Meals for Sensor-Augmented Pump and Closed-Loop Artificial Pancreas Therapy for Type 1 Diabetes Mellitus
543660DSTXXX10.1177/1932296814543660Journal of Diabetes Science and TechnologySrinivasan et al research-article2014 Original Article Novel Insulin Delivery Profiles for Mixed Meals for Sensor-Augmented
More informationDiAs Web Monitoring: A Real-Time Remote Monitoring System Designed for Artificial Pancreas Outpatient Trials
Journal of Diabetes Science and Technology Volume 7, Issue 6, November 2013 Diabetes Technology Society SYMPOSIUM DiAs Web Monitoring: A Real-Time Remote Monitoring System Designed for Artificial Pancreas
More informationAn Improved PID Switching Control Strategy for Type 1 Diabetes
An Improved PID Switching Control Strategy for Type 1 Diabetes Gianni Marchetti, Massimiliano Barolo, Lois Jovanovic, Howard Zisser, and Dale E. Seborg, Member, IEEE Department of Chemical Engineering
More informationArtificial Pancreas Using a Personalized Rule-Based Controller Achieves Overnight Normoglycemia in Patients with Type 1 Diabetes
DIABETES TECHNOLOGY & THERAPEUTICS Volume 16, Number 3, 2014 ª Mary Ann Liebert, Inc. DOI: 10.1089/dia.2013.0229 ORIGINAL ARTICLE Artificial Pancreas Using a Personalized Rule-Based Controller Achieves
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Haidar A, Legault L, Matteau-Pelletier L, et
More informationNumerous studies have demonstrated that utilization
DIABETES TECHNOLOGY & THERAPEUTICS Volume 18, Supplement 2, 2016 ª Mary Ann Liebert, Inc. DOI: 10.1089/dia.2015.0369 ORIGINAL ARTICLE Use of Glucose Rate of Change Arrows to Adjust Insulin Therapy Among
More informationPrandial insulin dosing using run-to-run control: application of clinical data and medical expertise to define a suitable performance metric
Paper No. 243a Prandial insulin dosing using run-to-run control: application of clinical data and medical expertise to define a suitable performance metric Cesar C. Palerm, Howard Zisser, Wendy C. Bevier,
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationClinical Validity of Insulin Bolus Calculators
Clinical Validity of Insulin Bolus Calculators Howard A. Wolpert, MD Senior Physician, Joslin Diabetes Center Associate Professor, Harvard Medical School Director, Joslin Institute for Technology Translation
More informationThe Diabetes Self Management Insulin Pump Therapy Program
The Diabetes Self Management Insulin Pump Therapy Program Is part of a Nationally recognized program taught by CPT s Offers classes during the daytime in a three part series: PRE-PUMP CLASS SALINE START
More informationInsulin Pump Management and Continuous Glucose Monitoring Systems (CGMS)
Insulin Pump Management and Continuous Glucose Monitoring Systems (CGMS) Faith Daily, RN, BSN, CDE, CPT Certified Diabetes Educator/Insulin Pump Trainer August 16, 2014 Why Pump Therapy? Mimics normal
More informationInsulin Pump Therapy and Continuous Glucose Sensor Use in the Management of Diabetes Mellitus
Insulin Pump Therapy and Continuous Glucose Sensor Use in the Management of Diabetes Mellitus Louis Haenel, IV, DO, FACOI, FACE Endocrinology Roper Hospital Charleston, SC Dr. Louis Haenel IV has disclosed
More informationOFFICE OF CATHOLIC SCHOOLS DIOCESE OF ARLINGTON DIABETES MEDICAL MANAGEMENT PLAN Page 1 of 5 TO BE COMPLETED BY PARENT OR GUARDIAN
PART I OFFICE OF CATHOLIC SCHOOLS DIOCESE OF ARLINGTON DIABETES MEDICAL MANAGEMENT PLAN Page 1 of 5 TO BE COMPLETED BY PARENT OR GUARDIAN Student School Date of Birth Date of Diagnosis Grade/ Teacher Physical
More informationMedical Policy Insulin Pumps
Medical Policy Insulin Pumps Document Number: 027 Authorization required Insulin Pumps & supplies Notification within 24 hours of service or next business day No Prior Authorization Not covered Pulsatile
More informationINPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
More informationDiabetes Health Care Plan
The Public Schools of Brookline School Health Services of Plan: Diabetes Health Care Plan To be completed by the student s health care team and parents/guardian. Plan will be kept with the school nurse
More informationA new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration
of nurse A new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration 1. Check times for point of care meter blood glucose testing. Pre-Breakfast
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationDiabetes Self Management Training Insulin Pump Follow Up
701 East Marshall Street, West Chester, PA 19380 www.chestercountyhospital.org 610.431.5000 Diabetes Self Management Training Insulin Pump Follow Up Patient Name: Visit Date: Time: To prepare for your
More informationAlgorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
More informationSYSTEMS AND INFORMATION ENGINEERING
DEPARTMENT OF SYSTEMS AND INFORMATION ENGINEERING SIEFALL 2015 Associate Systems and Information Engineering Professor Gregory J. Gerling has his finger on the pulse of interdisciplinary research, bridging
More informationResident s Guide to Inpatient Diabetes
Resident s Guide to Inpatient Diabetes 1. All patients with diabetes of ANY TYPE, regardless of reason for admission, must have a Hemoglobin A1C documented in the medical record within 24 hours of admission
More informationCLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies
Insulins CLASS OBJECTIVES Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies INVENTION OF INSULIN 1921 The first stills used to make insulin
More informationMedical Benefit Effective Date: 04/01/11 Next Review Date: 01/13 Preauthorization* Yes Review Dates: 07/07, 07/08, 07/09, 01/10, 01/11, 01/12
Continuous or Intermittent Monitoring of Glucose in Interstitial (10120) Medical Benefit Effective Date: 04/01/11 Next Review Date: 01/13 Preauthorization* Yes Review Dates: 07/07, 07/08, 07/09, 01/10,
More informationTherapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2
Ministry of Health, Malaysia 2010 First published March 2011 Perkhidmatan Diabetes dan Endokrinologi Kementerian Kesihatan Malaysia Practical guide to Insulin Therapy in Type 2 Diabetes Mellitus Quick
More informationImplications of Meal Library & Meal Detection to Glycemic Control of Type 1 Diabetes Mellitus through MPC Control
Proceedings of the 17th World Congress The International Federation of Automatic Control Seoul, Korea, July 6-11, 28 Implications of Meal Library & Meal Detection to Glycemic Control of Type 1 Diabetes
More informationUser guide Basal-bolus Insulin Dosing Chart: Adult
Contacts and further information Local contact Clinical pharmacy or visiting pharmacy Diabetes education service Director of Medical Services Visiting or local endocrinologist or diabetes physician For
More informationNONINSULIN-DEPENDENT diabetes mellitus
0021-972X/97/$03.00/0 Vol. 82, No. 8 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1997 by The Endocrine Society An Overnight Insulin Infusion Algorithm Provides Morning
More informationA Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Basal Dosing
Journal of Diabetes Science and Technology Volume 1, Issue 1, January 2007 Diabetes Technology Society ORIGINAL ARTICLES A Prospective Evaluation of Insulin Dosing Recommendations in Patients Allen B.,
More informationCalculating Insulin Dose
Calculating Insulin Dose First, some basic things to know about insulin: Approximately 40-50% of the total daily insulin dose is to replace insulin overnight, when you are fasting and between meals. This
More informationA Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Bolus Dosing
Journal of Diabetes Science and Technology Volume 1, Issue 1, January 2007 Diabetes Technology Society ORIGINAL ARTICLES A Prospective Evaluation of Insulin Dosing Recommendations in Patients Allen B.,
More informationClinical Policy Title: Disposable Continuous Subcutaneous Insulin Infusion Pumps
Clinical Policy Title: Disposable Continuous Subcutaneous Insulin Infusion Pumps Clinical Policy Number: 06.02.01 Effective Date: March 1, 2014 Initial Review Date: Nov. 20 th, 2013 Most Recent Review
More informationUS Diabetic Devices Industry Research Report: KenResearch
US Diabetic Devices Industry Research Report: KenResearch by KenResearch - Monday, February 24, 2014 https://www.kenresearch.com/blog/2014/02/us-diabetic-devices-industry-research-report-kenresearch/ The
More informationALVIN INDEPENDENT SCHOOL DISTRICT Diabetes Medical Management Plan
ALVIN INDEPENDENT SCHOOL DISTRICT Diabetes Medical Management Plan of Plan: School Year (must be current): This plan should be completed by the student s personal health care team and parents/guardian.
More informationDiabetes Medical Management Plan (DMMP)
Diabetes Medical Management Plan (DMMP) This plan should be completed by the student s personal diabetes health care team, including the parents/guardian. It should be reviewed with relevant school staff
More informationDiabetes Management and Treatment Plan for School (For the insulin pump student)
Lafayette School Corporation Health Services Diabetes Management and Treatment Plan for School (For the insulin pump student) Effective Dates: This plan should be complete by the student s personal health
More informationClinical Policy Title: Disposable Continuous Subcutaneous Insulin Infusion Pumps
Clinical Policy Title: Disposable Continuous Subcutaneous Insulin Infusion Pumps Clinical Policy Number: 06.02.01 Effective Date: March 1, 2014 Initial Review Date: Nov. 20, 2013 Most Recent Review Date:
More information4/7/2015 CONFLICT OF INTEREST DISCLOSURE OBJECTIVES. Conflicts of Interest None Heather Rush. Heather M. Rush, APRN, CDE Louisville, KY
Heather M. Rush, APRN, CDE Louisville, KY CONFLICT OF INTEREST DISCLOSURE Conflicts of Interest None Heather Rush A conflict of interest exists when an individual is in a position to profit directly or
More informationSchool Nurse Role in Care and Management of the Child with Diabetes in Colorado Schools and Child Care Settings Position Statement 1 POSITION It is
Schools and Child Care Settings Position Statement 1 POSITION It is the position of the Colorado Diabetes Resource Nurses that the school nurse is the only school staff member who has the skills, knowledge
More informationInsulin dosage based on risk index of Postprandial Hypo- and Hyperglycemia in Type 1 Diabetes Mellitus with uncertain parameters and food intake
based on risk index of Postprandial Hypo- and Hyperglycemia in Type 1 Diabetes Mellitus with uncertain parameters and food intake Remei Calm 1, Maira García-Jaramillo 1, Jorge Bondia 2, Josep Vehí 1 1
More informationTaking Insulin Pumps to School. Rachel Calendo, MS, RN, CPNP, CDE, Martha Cuevas, RN, BSN, CPT
Taking Insulin Pumps to School Rachel Calendo, MS, RN, CPNP, CDE, Martha Cuevas, RN, BSN, CPT Insulin Pumps Today A micro-computer, about the size of a pager Programmed to deliver both a preset amount
More informationFunc%onal insulin therapy: rela%onship to carbohydrate intake
Func%onal insulin therapy: rela%onship to carbohydrate intake Prof. Andrej Janež MD, PhD University Medical Centre Ljubljana, Slovenia Conflict of interests Merck Sharp&Dohme, Novo Nordisk, NovarEs, Boehringer
More informationIntroduction. We hope this guide will aide you and your staff in creating a safe and supportive environment for your students challenged by diabetes.
Introduction Diabetes is a chronic disease that affects the body s ability to metabolize food. The body converts much of the food we eat into glucose, the body s main source of energy. Glucose is carried
More information(30251) Insulin SQ Prandial Carbohydrate
Diagnosis Patient MUST BE educated using carbohydrate counting for prial insulin coverage before hospitalization to be eligible for this order set Nursing Metered Glucose (Single Select Section) Metered
More informationHealth Policy Advisory Committee on Technology
Health Policy Advisory Committee on Technology Technology Brief Update Closed-loop Insulin Delivery System for the management of hypoglycaemia November 2012 State of Queensland (Queensland Health) 2012
More informationIntroducing DEXCOM STUDIO INTUITIVE. FOCUSED. SIMPLIFIED. HELP TAKE the GUESSWORK OUT of GLUCOSE PATTERN MANAGEMENT
Introducing DEXCOM STUDIO Continuous Glucose Monitoring Software INTUITIVE. FOCUSED. SIMPLIFIED. HELP TAKE the GUESSWORK OUT of GLUCOSE PATTERN MANAGEMENT Glucose Pattern Management A Guide to Interpreting
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationSchool Year 20 / 20. Diabetes Health Care Plan for Southgate Schools
School Year 20 / 20 Diabetes Health Care Plan for Southgate Schools Diabetes Medical Management Plan, Initialized Healthcare Plan and Physician Orders Part A: Contact Information must be completed by the
More informationDiabetes Insulin Pump Health Care Plan District Nurse Phone: 262-560-2104 District Nurse Fax: 262-560-2106
EMPOW ERING A COMMUNITY OF LEARNERS AND LEADERS Diabetes Insulin Pump Health Care Plan District Nurse Phone: 262-560-2104 District Nurse Fax: 262-560-2106 Student DOB School Grade Doctor Phone School Year
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More informationGlycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol
Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Ruth LaCasse Kalish, RPh Department of Pharmacy Objectives Review the current practice at UConn Health with sliding
More informationPresent and Future of Insulin Therapy: Research Rationale for New Insulins
Present and Future of Insulin Therapy: Research Rationale for New Insulins Current insulin analogues represent an important advance over human insulins, but clinically important limitations of these agents
More informationObjectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES. Historical Perspective. Insulin Pumps in Pregnancy. Insulin Pumps in the US
Objectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES Jo M. Kendrick, APN BC, CDE jkendric@utmck.edu Describe indications and contraindications for insulin pump use in hospitalized patients Differentiate
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationTen Ways to Prevent Insulin-Use Errors in Your Hospital. ASHP Research and Education Foundation May 14, 2014
Ten Ways to Prevent Insulin-Use Errors in Your Hospital ASHP Research and Education Foundation May 14, 2014 To Ask Questions and Adjust the Control Panel Expand or Collapse Type your question here Faculty
More informationBasal and Bolus Insulin 7/16/2014. Jackie Aday RN, BSN, CDE Jeni Neighbors RN, BSN, CDE. BASAL: Small amount of insulin infused every few minutes
Jackie Aday RN, BSN, CDE Jeni Neighbors RN, BSN, CDE Insulin Pump Therapy Open looped system in which a small amount of insulin is continuously infused through a cannula or needle (basal rate) Larger doses
More informationDear Parent/Guardian and Physician of
DIABETIC MANAGEMENT PLAN Parent Consent and Physician Authorization POWAY UNIFIED SCHOOL DISTRICT HEALTH SERVICES 15250 Avenue of Science San Diego CA 92128 Dear Parent/Guardian and Physician of California
More informationHealth Professional s. Guide to INSULIN PUMP THERAPY
Health Professional s Guide to INSULIN PUMP THERAPY Table of Contents Introduction Presenting Insulin Pump Therapy to Your Patients When Your Patient Chooses the Pump Estimates for Starting Insulin Pump
More informationINTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL
INTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL Presented by: Leyda Callejas PGY5 Endocrinology, Diabetes and Metabolism Acknowledgements: Dr. P Orlander Dr. V Lavis Dr. N Shah
More informationShould We Count Fat and Protein in Bolus Insulin Dose Calculation: Does Carbohydrate Counting Work? Howard A. Wolpert, MD
Should We Count Fat and Protein in Bolus Insulin Dose Calculation: Does Carbohydrate Counting Work? Howard A. Wolpert, MD Carbohydrate to Insulin Ratio, circa 1935 Standard Insulin Replacement Regimen
More informationInsulin Therapy. Endocrinologist. H. Delshad M.D. Research Institute For Endocrine Sciences
Insulin Therapy H. Delshad M.D Endocrinologist Research Institute For Endocrine Sciences Primary Objectives of Effective Management A1C % 9 8 Diagnosis SBP mm Hg LDL mg/dl 7 145 130 140 100 Reduction of
More informationTelephone: Home Work Cell E-mail Address Father/Guardian: Address:
SAMPLE Diabetes Medical Management Plan/Individualized Healthcare Plan Part A: Contact Information must be completed by the parent/guardian. Part B: Diabetes Medical Management Plan (DMMP) must be completed
More informationLead Clinician(S) (DATE) Approved by Diabetes Directorate on: Approved by Medicines Safety Group on: This guideline should not be used after end of:
Guideline for members of the diabetes team and dietetic department for advising on insulin dose adjustment and teaching the skills of insulin dose adjustment to adults with type 1 or type 2 diabetes mellitus
More informationExternal Insulin Pumps Corporate Medical Policy
External Insulin Pumps Corporate Medical Policy File name: External Insulin Pumps File code: UM.DME.02 Origination: 4/2006 Last Review: 02/2014 (ICD-10 remediation only) Next Review: 10/2014 Effective
More informationThe Artificial Pancreas Study - Diabetes
Winter 2008/9 The Artificial Pancreas (AP) studies are now well into the second year. In the past eighteen months we have completed a programme of three studies using our AP setup. STUDY 1 (The Pilot Study)
More informationEquipment and Supplies Checklist for Parents Student: DOB: School: Grade: Equipment and Supplies to be Provided by Parent. Parent Signature Date
Equipment and Supplies Checklist for Parents Student: DOB: School: Grade: Equipment and Supplies to be Provided by Parent Parent Signature Date Daily Snacks (for AM/PM snack times): Specify: Extra Snacks
More informationFDA Perspective on Closed-Loop Studies
FDA Perspective on Closed-Loop Studies Practical Ways to Achieve Targets in Diabetes Care July 19, 2014 Keystone, CO Courtney H. Lias, Ph.D. Office of In Vitro Diagnostic Device Evaluation and Safety Center
More informationCURRENT THERAPEUTIC RESEARCH
CURRENT THERAPEUTIC RESEARCH VOLUME 70, NUMBER I, FEBRUARY 2009 Case Series Adjusting the Basal Insulin Regimen of Patients With Type 1 Diabetes Mellitus Receiving Insulin Pump Therapy During the Ramadan
More informationBOLUS INSULIN DOSAGES H. Peter Chase, MD and Erin Cobry, BS
CHAPTER 6: BOLUS INSULIN DOSAGES H. Peter Chase, MD and Erin Cobry, BS WHAT IS BOLUS INSULIN? Bolus insulin dosages refer to the quick bursts of insulin given to cover the carbohydrates in meals or snacks
More informationBLOOD GLUCOSE MONITORING MEDICATION
DIABETES CARE FOR SCHOOL MEDICAL MANAGEMENT PLAN Most Recent A1C and Date: BLOOD GLUCOSE MONITORING Meter Type: Testing Independently: yes no Testing times: Before meals Two hours after insulin dosing
More informationGlucose Monitoring in Interstitial Fluid Diabetes
Medical Coverage Policy Subject: Continuous Glucose Monitoring in Interstitial Fluid Policy #: MED Current Effective Date: 11/10/14 Status: New Last Review Date: 11/10/14 Description/Scope Tight glucose
More informationInsulin Dose Adjustment REAL-Time CGMS Guidelines for Subjects on Pump Therapy
Insulin Dose Adjustment REAL-Time CGMS Guidelines for Subjects on Pump Therapy In addition to using the blood sugar logs to adjust your insulin doses every week, you should also use your continuous glucose
More informationYour Road Map to Diabetes Medication Administration Record (Part 1)
Your Road Map to Diabetes Medication dministration Record (Part 1) Ohio Revised ode (3313.713) is the education law that addresses prescriptive medication administration in Ohio schools. This OR lists
More informationContinuous Subcutaneous Insulin Infusion (CSII)
IMPORTANCE OF FOCUS CSII (Insulin pumps) have been used for more than 35 years. In the U.S. in 2005, the level of insulin pump penetration was estimated at 20 to 30% in patients with type 1 diabetes mellitus
More informationA Fuzzy Controller for Blood Glucose-Insulin System
Journal of Signal and Information Processing, 213, 4, 111-117 http://dx.doi.org/1.4236/jsip.213.4215 Published Online May 213 (http://www.scirp.org/journal/jsip) 111 Ahmed Y. Ben Sasi 1, Mahmud A. Elmalki
More informationTiming of insulin bolus in patients with type 1 diabetes: effect on glucose control and variability using CGMS
Timing of insulin bolus in patients with type 1 diabetes: effect on glucose control and variability using CGMS Idit F Liberty MD, Diabetes Unit, Soroka University Medical Center, Beer Sheva, Israel Aviv
More informationImplementing The Portland Protocol - Continuous Intravenous Insulin Infusion in your institution
Implementing The Portland Protocol - Continuous Intravenous Insulin Infusion in your institution Anthony P. Furnary, MD St Vincent Medical Center Providence Health Systems Portland, OR Phased Implementation
More informationType 1 Diabetes. Pennington Nutrition Series. Overview. About Insulin
Pennington Nutrition Series Healthier lives through education in nutrition and preventive medicine Pub No. 32 Type 1 Diabetes Overview Type 1 Diabetes (DM) is usually diagnosed in children and young adults.
More informationClosed loop insulin delivery systems
: 170-174, 2009 Closed loop insulin delivery systems R. Hovorka 1 DB. Dunger 2 1 Principal Research Associate, Diabetes Modelling Group, Department of Paediatrics, University of Cambridge, Cambridge, UK.
More information2011 EBM-hyperglycemia
嗎 2011 EBM-hyperglycemia 陳 莉 瑋 醫 師 一 定 要 打 打 bolus insulin? 用 FinePrint 列 印 - 可 在 www.ahasoft.com.tw/fineprint 訂 購 Question 1 Is bolus insulin necessary in DKA? P:DKA adult patient I:initial bolus insulin+insulin
More informationInsulin/Diabetes Calculations
Insulin/Diabetes Calculations Dr. Aipoalani St Lukes Endocrinology Goals Describe various calculations for insulin dosing Understand importance of the total daily dose (TDD) of insulin Be able to calculate
More informationDiabetes Medical Management Plan
Diabetes Medical Management Plan 1 School District: School: School Year: Grade: Student Name: DOB: Provider Name: Phone #: Fax #: Blood Glucose Monitoring at School Blood Glucose Target Range: - mg/dl
More informationSiphon Effects on Continuous Subcutaneous Insulin Infusion Pump Delivery Performance
Journal of Diabetes Science and Technology Volume 4, Issue 1, January 2010 Diabetes Technology Society ORIGINAL ARTICLES Siphon Effects on Continuous Subcutaneous Insulin Infusion Pump Delivery Performance
More informationInsulin Pump Therapy. Jen Block, MSN, RN, CDE Stanford University Department of Pediatric Endocrinology
Insulin Pump Therapy Jen Block, MSN, RN, CDE Stanford University Department of Pediatric Endocrinology Disclosures Member of Clinical Advisory Panel for Tandem Work on a variety of clinical trials funded
More informationManagement of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)
Management of Diabetes in the Elderly Sylvia Shamanna Internal Medicine (R1) Case 74 year old female with frontal temporal lobe dementia admitted for prolonged delirium and frequent falls (usually in the
More informationRiley Hospital for Children General Diabetes Medical Management Information- Injections
Riley Hospital for Children General Diabetes Medical Management Information- Injections 1. HEALTH CARE SUPERVISION All school support staff, including: secretaries, cafeteria staff, custodians and bus
More informationInsulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types
Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by
More informationIntensifying Insulin Therapy
Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning
More informationSponsor / Company: Sanofi Drug substance(s): HOE901 (insulin glargine)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More information